Saturday, October 31, 2026

NetEase Stock Bullish Momentum With A 4.77% Jump On Friday

ViaNews Editorial Team

November 20, 2020

NetEase Stock Bullish Momentum With A 4.77% Jump On Friday

Shares of NetEase rose 4.77% to $93.48 at 10:48 EST on Friday, after one succeed sessions in a rows of gains. The Nasdaq Stock Market is rising 0.06% to $11911.7, after one sequential sessions in a rows of gains, on what seems, so far, a somewhat positive trend exchanging session on The Nasdaq Stock Market.

NetEase's last close was $89.22, below its 52-week high of $103.53.

NetEase's sales growth is 32.9% for the present quarter and 38.3% for the next. The company's growth estimates for the present quarter is a negative 2.4% and positive 7.1% for the next.

NetEase's stock is valued at $93.48 at 10:48 EST, below its 52-week high of $103.53 and way higher than its 52-week low of $53.17.

NetEase's value is higher than its 50-day moving average of $88.53 and above its 200-day moving average of $88.26.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com